La chaîne d'options affiche les données clés des options sur actions de Centene à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour Centene..

Centene (NYSE:CNC) Stock, Chaîne d'Options

Centene

Centene is a managed care organization that focuses on government-sponsored healthcare plans, including Medicaid, Medicare, and the individual exchanges. Centene served 22 million medical members as of December 2024, mostly in Medicaid (about 60% of membership), the individual exchanges (about 20%), and Medicare (about 5%). The company also has a military contract and provides Medicare Part D pharmaceutical plans.

Centene Corp

Canna Corp

CHINA NUCLEAR ENERGY TECH by CHINA NUCLEAR ENERGY TECHNOLOGY CORP LTD.

Coincheck Group NV

CANCER CAPITAL CORP by Cancer Capital Corp.

Cancer Capital Corp

CONNECTED MEDIA TECHS INC by Connected Media Technologies, Inc.

Connected Media Technologies Inc

CHUN CAN CAPITAL GROUP by Chun Can Capital Group

Chun Can Capital Group

Core Nickel Corp

CONDUIT CAPITAL LTD ORD by Conduit Capital Ltd.

ETF Series Solutions Range Cancer Therapeutics ETF

CHINA CASTSON 81 FINCE by CHINA CASTSON 81 FINANCE CO.

China Teletech Holding Inc

Cluster Group Holdings Ltd Co

In the preceding three months, 15 analysts have released ratings for Centene (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>), presenting a wide array of perspectives from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">9</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">6</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $50.93, with a high estimate of $84.00 and a low estimate of $30.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 32.16%. 
<img src="https://www.benzinga.com/files/images/story/2025/1753128067_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The perception of Centene by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ryan Langston</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Hold</td>
<td>$33.00</td>
<td>$73.00</td>
</tr>
<tr>
<td>Ryan MacDonald</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$42.00</td>
<td>$84.00</td>
</tr>
<tr>
<td>Kevin Fischbeck</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Underperform</td>
<td>$30.00</td>
<td>$52.00</td>
</tr>
<tr>
<td>Michael Wiederhorn</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$51.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Ann Hynes</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$40.00</td>
<td>$71.00</td>
</tr>
<tr>
<td>Ricky Goldwasser</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$33.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$45.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Kevin Fischbeck</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$52.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$65.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>A.J. Rice</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$45.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>John Stansel</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$48.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Ricky Goldwasser</td>
<td>Morgan Stanley</td>
<td>Announces</td>
<td>Overweight</td>
<td>$70.00</td>
<td>-</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$65.00</td>
<td>$84.00</td>
</tr>
<tr>
<td>David Windley</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Hold</td>
<td>$61.00</td>
<td>$64.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$84.00</td>
<td>$93.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Centene. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Centene compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Centene's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Centene's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/CNC/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Centene analyst ratings.</a>
<h2>Unveiling the Story Behind Centene</h2>
Centene is a managed care organization that focuses on government-sponsored healthcare plans, including Medicaid, Medicare, and the individual exchanges. Centene served 22 million medical members as of December 2024, mostly in Medicaid (about 60% of membership), the individual exchanges (about 20%), and Medicare (about 5%). The company also has a military contract and provides Medicare Part D pharmaceutical plans.
<h3>Unraveling the Financial Story of Centene</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: Over the 3M period, Centene showcased positive performance, achieving a revenue growth rate of 15.38% as of 31 March, 2025. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Centene's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of 2.81%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Centene's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 4.83%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Centene's ROA stands out, surpassing industry averages. With an impressive ROA of 1.55%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.66.
<h2>Analyst Ratings: Simplified</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

The Analyst Verdict: Centene In The Eyes Of 15 Experts

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>Needham analyst Gil Blum downgraded the rating for Sarepta Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) from Hold to Underperform. Sarepta Therapeutics shares closed at $14.07 on Friday. <a href="https://www.benzinga.com/quote/srpt/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Barclays analyst Seth Sigman downgraded Target Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGT#NYSE">TGT</a>) from Equal-Weight to Underweight and announced a $91 price target. Target shares closed at $103.46 on Friday. <a href="https://www.benzinga.com/quote/tgt/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Leerink Swann analyst Mani Foroohar downgraded Sarepta Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) from Outperform to Market Perform and cut the price target from $45 to $10. Sarepta Therapeutics shares closed at $14.07 on Friday. <a href="https://www.benzinga.com/quote/srpt/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Truist Securities analyst Patrick Scholes downgraded Royal Caribbean Cruises Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RCL#NYSE">RCL</a>) from Buy to Hold but raised the price target from $275 to $337. Royal Caribbean shares closed at $350.10 on Friday. <a href="https://www.benzinga.com/quote/rcl/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>TD Cowen analyst Ryan Langston downgraded Centene Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) from Buy to Hold and cut the price target from $73 to $33. Centene shares closed at $27.95 on Friday. <a href="https://www.benzinga.com/quote/cnc/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying TGT stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="579" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/21083022/image-278-1024x579.png" alt="" class="wp-image-993565" style="width:569px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/21083022/image-278-1024x579.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/21083022/image-278-300x170.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/21083022/image-278-768x434.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/21083022/image-278.png 1142w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/07/46491269/top-2-energy-stocks-that-may-fall-off-a-cliff-this-quarter-2">Top 2 Energy Stocks That May Fall Off A Cliff This Quarter</a></li>
</ul>
Photo via Shutterstock

News

Downgrades

Pre-Market Outlook

Markets

Trading Ideas

ALNY

SRPT

This Target Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday

TD Cowen analyst Ryan Langston downgrades Centene (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) from Buy to Hold and lowers the price target from $73 to $33.

Price Target

TD Cowen Downgrades Centene to Hold, Lowers Price Target to $33

These ten large-cap stocks were the worst performers last week. Are they a&nbsp;<a target="_blank" href="https://www.benzinga.com/trading-ideas" rel="noreferrer noopener">part of your portfolio</a>?
<ol class="wp-block-list">
<li>Elevance Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELV#NYSE">ELV</a>) shares decreased 17.96% this week after the company lowered its <a href="https://www.benzinga.com/markets/earnings/25/07/46468951/elevance-health-hit-by-medicaid-troubles-trims-outlook" target="_blank" rel="noreferrer noopener">fiscal year 2025 adjusted earnings guidance</a>. The company missed earnings in the second quarter. Also, multiple analysts lowered their <a href="https://www.benzinga.com/quote/ELV/analyst-ratings" target="_blank" rel="noreferrer noopener">price forecast on the stock</a>.</li>
<li>Waters Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAT#NYSE">WAT</a>) fell 9.50% this week  after the company agreed to combine Becton, Dickinson and Company&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BDX#NYSE">BDX</a>) Biosciences &amp; Diagnostic Solutions <a href="https://www.benzinga.com/m-a/25/07/46389674/bectons-biosciences-and-diagnostics-arm-slated-to-join-waters-in-17-5-billion-merger\" target="_blank" rel="noreferrer noopener">business with Waters</a>. Also, Wells Fargo downgraded the stock from Overweight to Equal-Weight and lowered its <a href="https://www.benzinga.com/quote/WAT/analyst-ratings" target="_blank" rel="noreferrer noopener">price forecast from $420 to $330</a>.</li>
<li>Natera, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NASDAQ">NTRA</a>) slumped 13.19% this week.</li>
<li>Centene Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) shares fell 10.49% this week amid a selloff in the sector following Elevance&#8217;s recent soft guidance and broader concerns <a href="https://www.benzinga.com/trading-ideas/movers/25/07/46474212/centene-stock-hit-a-new-52-week-low-today-whats-going-on" target="_blank" rel="noreferrer noopener">over rising medical costs</a>.</li>
<li>Venture Global, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VG#NYSE">VG</a>) shares slumped 11.27% this week. The company and ENI (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/E#NYSE">E</a>) of Italy announced the execution of a new Sales and Purchase Agreement (SPA) for the purchase of 2 million tonnes per annum (MTPA) of liquefied natural gas (LNG) from CP2 LNG, Venture Global&#8217;s third project, for 20 years.&nbsp;</li>
<li>Schlumberger N.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLB#NYSE">SLB</a>) stock slumped 8.87% this week after the company reported second-quarter financial results, issued expectations for flat-to-low single-digit revenue growth in the second half of 2025, and stated that tariffs will cost <a href="https://www.benzinga.com/markets/earnings/25/07/46492669/slb-trims-2025-capital-spending-prioritizing-efficiency-post-championx-deal" target="_blank" rel="noreferrer noopener">between 20-to-40 basis points of margin</a>. Additionally, Piper Sandler lowered its price forecast <a href="https://www.benzinga.com/quote/slb/analyst-ratings" target="_blank" rel="noreferrer noopener">from $44 to $42</a>.</li>
<li>Penske Automotive Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PAG#NYSE">PAG</a>) shares decreased 9.79% this week after JP Morgan lowered the price target from $160 to $155 <a href="https://www.benzinga.com/quote/PAG/analyst-ratings" target="_blank" rel="noreferrer noopener">while maintaining an Underweight rating</a>.</li>
<li>Stellantis N.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STLA#NYSE">STLA</a>) stock declined 7.72% this week after the firm announced it would be pulling the plug on the development of its Hydrogen fuel cell technology, citing no potential in the <a href="https://www.benzinga.com/markets/tech/25/07/46437558/stellantis-abandons-hydrogen-vehicle-plans-citing-weak-infrastructure-and-incentives-report" target="_blank" rel="noreferrer noopener">sector in the mid-term future</a>.</li>
<li>ASML Holding N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASML#NASDAQ">ASML</a>) shares fell 7.39% this week after the company said it <a href="https://www.benzinga.com/markets/equities/25/07/46438500/asml-stock-plunges-nearly-8-in-wednesday-pre-market-whats-going-on">cannot confirm 2026 growth</a> outlook after strong second quarter earnings.</li>
<li>TechnipFMC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FTI#NYSE">FTI</a>) stock fell 7.25% this week after BTIG analyst Greg Lewis downgraded the <a href="https://www.benzinga.com/quote/fti/analyst-ratings" target="_blank" rel="noreferrer noopener">company from Buy to Neutral</a>.</li>
</ol>
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/07/46507927/blackstone-backs-out-of-tiktok-us-deal-as-trump-deadline-looms-china-opposition-mounts-report" target="_blank" rel="noreferrer noopener">Blackstone Backs Out Of TikTok US Deal As Trump Deadline Looms, China Opposition Mounts: Report</a></li>
</ul>
Photo courtesy Skorzewiak via Shutterstock

Large Cap

Movers

ASML

streetTRACKS Dow Jones U.S. Large Cap Value Index Fund

NTRA

STLA

Schlumberger, Stellantis And ASML Holding Are Among Top 10 Large Cap Losers Last Week (July 14-July 18): Are The Others In Your Portfolio?

WIIM

Shares of health insurers are trading lower amid a selloff in the sector following Elevance's recent soft guidance and broader concerns over rising medical costs.

<a href="https://www.wsj.com/health/healthcare/obamacare-insurers-seek-double-digit-premium-hikes-next-year-454f1e1c" title="https://www.wsj.com/health/healthcare/obamacare-insurers-seek-double-digit-premium-hikes-next-year-454f1e1c">https://www.wsj.com/health/healthcare/obamacare-insurers-seek-double-digit-premium-hikes-next-year-454f1e1c</a>

Biotech

General

Reported Earlier: 'Obamacare Insurers Seek Double-Digit Premium Hikes Next Year; Some Enrollees Could Be Hit With Increases Of More Than 20% Because Of Federal Changes And Higher Health Expenses' - WSJ Exclusive

https://www.nytimes.com/2025/07/18/health/health-insurance-prescription-claim-denials.html#:~:text=Prescription%20drug%20denials%20by%20private,nation's%20private%20health%20insurance%20system.

ALHC

Reported Earlier: 'Health Insurers Are Denying More Drug Claims, Data Shows' - NY Times

Shares of Centene Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) are trading lower on Thursday, hitting a new 52-week low, as worsening news from a key competitor intensified investor fears about the profitability of government-sponsored health plans. 
What To Know: The sell-off was triggered by Elevance Health, which <a href="https://www.benzinga.com/markets/earnings/25/07/46468951/elevance-health-hit-by-medicaid-troubles-trims-outlook">reported</a> a miss on second-quarter earnings and drastically slashed its full-year profit guidance, validating the market pressures Centene itself had recently flagged.
Elevance cut its 2025 adjusted earnings forecast from over $34 per share to approximately $30, citing "elevated medical cost trends" in its Affordable Care Act (ACA) and Medicaid businesses. The company's benefit expense ratio swelled, indicating it was paying out more than expected for member medical care, a direct hit to its bottom line.
This announcement pours salt on an open wound for Centene, a company heavily focused on the ACA marketplace and Medicaid. Earlier in July, Centene's stock suffered a <a href="https://www.benzinga.com/trading-ideas/movers/25/07/46248507/centene-cnc-stocks-historic-drop-what-investors-need-to-know">historic collapse</a> after it withdrew its own 2025 financial outlook. 
The company's decision followed an actuarial data review showing its member base was sicker and more expensive than projected, leading to an anticipated $1.8 billion reduction in risk adjustment revenue.
Elevance's guidance shock confirms that the high medical costs and risk-pricing challenges are a sector-wide crisis, not a problem isolated to Centene.
Benzinga Edge Rankings: According to <a href="http://benzinga.grsm.io/register174">Benzinga Edge</a>, which ranks stocks based on four critical factors, Centene exhibits a distinct profile of strengths and weaknesses. The stock scores exceptionally well on Value, with a rating of 91.06, suggesting it is significantly undervalued compared to its peers or fundamental worth. 
It also shows solid Growth potential with a score of 69.56. However, these positive attributes are sharply contrasted by extremely low scores in Momentum (6.04) and Quality (5.46). 
This combination indicates that while the stock may be cheap with good growth prospects, its recent price performance has been very poor and its underlying financial health could be a concern.
Price Action: According to data from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, CNC shares are trading lower by 2.93% to $29.52 Thursday morning. The stock has a 52-week high of $80.59 and a 52-week low of $29.30.
Read Also: <a href="https://www.benzinga.com/news/health-care/25/07/46396470/elevance-steps-in-as-unitedhealth-delays-will-it-set-the-tone-for-insurers">Elevance Steps In As UnitedHealth Delays — Will It Set The Tone For Insurers?</a>
<h2 class="wp-block-heading">How To Buy CNC Stock</h2>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in Centene&#8217;s case, it is in the Health Care sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
Image: Shutterstock

Centene Stock Hit A New 52-Week Low Today: What's Going On?

Shares of health insurance stocks are trading lower in sympathy with Elevance Health after the company reported mixed Q2 financial results and cut its FY25 adjusted EPS guidance.

Elevance Health Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELV#NYSE">ELV</a>) shares plummeted nearly 12% on Thursday after the health insurer reported second-quarter 2025 adjusted earnings that missed analyst expectations and significantly lowered its full-year guidance, overshadowing strong revenue growth.
The company reported second-quarter 2025 revenues of $49.42 billion, up 14.3% year over year, higher than the consensus of $48.34 billion. 
The increase was driven by higher premium yields in the Health Benefits segment, recently closed acquisitions, and growth in Medicare Advantage membership, partially offset by membership attrition in the Medicaid business.
Also Read: <a target="_blank" href="https://www.benzinga.com/trading-ideas/movers/25/07/46280387/unitedhealth-centene-hit-hard-by-guidance-shock-trumps-medicaid-push" rel="noreferrer noopener">UnitedHealth, Centene Hit Hard By Guidance Shock, Trump&#8217;s Medicaid Push</a>
Elevance Health reported adjusted earnings of $8.84 per share, missing <a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">the consensus of $9.20</a>.
The benefit expense ratio was 88.9%, an increase of 260 basis points year over year, reflecting higher medical cost trend primarily in Medicaid business and <a href="https://www.benzinga.com/pressreleases/25/07/b46461908/elevance-health-reports-second-quarter-2025-results" target="_blank" rel="noreferrer noopener">ACA health plans</a>. 
The operating expense ratio was 10.1 percent, an improvement of 160 basis points. The adjusted operating expense ratio was 10%, an improvement of 140 basis points, primarily driven by expense leverage associated with growth in operating revenue and ongoing expense discipline as the company prioritizes investments to support long-term strategy.
Health Benefits segment operating revenue was $41.6 billion in the second quarter of 2025, up 12% compared to the prior year quarter, driven primarily by higher premium yields, recently closed acquisitions, and growth in Medicare Advantage membership, partially offset by lower Medicaid membership.
Medical membership totaled approximately 45.6 million, a decline of 212 thousand from the first quarter of 2025, driven by lower Medicaid membership and attrition resulting from lower effectuation rates in Individual ACA business.
Operating revenue for Carelon was $18.1 billion, up 36%, driven by recent acquisitions in home health and pharmacy services, growth in CarelonRx product revenue, and the scaling of risk-based capabilities in Carelon Services.
<h2 class="wp-block-heading">Guidance</h2>
Elevance Health lowered its fiscal year 2025 adjusted earnings guidance <a href="https://www.benzinga.com/general/health-care/25/04/44927473/despite-medicaid-pressure-elevance-health-delivers-strong-q1-performance-reiterates-profit-outlook" target="_blank" rel="noreferrer noopener">from $34.15-$34.85 per share</a> to approximately $30, versus the consensus of $34.40.
&#8220;We are updating our outlook to reflect elevated medical cost trends in ACA and slower rate alignment in Medicaid. While the external environment continues to evolve, we are focused on the areas within our control &#8211; managing healthcare costs, deploying targeted investments in advanced technology and value-based care delivery, and reinforcing the operational foundation that supports long-term value creation,&#8221; said Gail Boudreaux, President and CEO, in a statement on Thursday.
<h2 class="wp-block-heading">Industry Context and Peer Impact</h2>
This guidance shock from Elevance Health follows a similar move by Centene Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>). Centene recently withdrew its entire 2025 GAAP and adjusted diluted EPS guidance. This decision by Centene was prompted by its initial review of 2025 industry data from Wakely, <a href="https://www.benzinga.com/news/health-care/25/07/46396470/elevance-steps-in-as-unitedhealth-delays-will-it-set-the-tone-for-insurers">an independent actuarial firm</a>. 
Centene&#8217;s analysis indicated lower-than-anticipated market growth and significantly higher implied market morbidity (prevalence of illness) in their Health Insurance Marketplace states, leading to a substantial reduction in their expected risk adjustment revenue transfer. 
These events highlight a broader industry concern among health insurers regarding elevated medical costs and challenges in accurately predicting risk and pricing in government-sponsored programs like Medicaid and the ACA.
Price Action: ELV stock is trading lower by 11.8% to $303.92 at last check Thursday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/earnings/25/07/46461683/netflixs-q2-earnings-could-impress-analyst-predicts-30-profit-growth-from-ads-price-hikes" target="_blank" rel="noreferrer noopener">Netflix&#8217;s Q2 Earnings Could Impress: Analyst Predicts 30% Profit Growth From Ads, Price Hikes</a></li>
</ul>
Photo by Jonathan Weiss via Shutterstock

Earnings

Guidance

Health Care

Elevance Health Hit By Medicaid Troubles, Trims Outlook

For approximately 15 years, or 60 quarters, UnitedHealth Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) has consistently reported better-than-expected quarterly earnings.
However, in the <a href="https://www.benzinga.com/general/health-care/25/01/43025159/unitedhealth-q4-earnings-revenue-falls-short-medical-ratio-rises-to-85-5-stock-falls" target="_blank" rel="noreferrer noopener">fourth quarter of 2024</a>, the insurance giant reported mixed earnings, and in the first quarter of 2025, earnings fell short of expectations. UnitedHealth blamed rising medical costs.
According to a Bloomberg report, the company extended its 15-year streak of beating Wall Street earnings expectations in 2024, but only with the help of asset sales that analysts later described as unusual and <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">potentially misleading</a>.
The healthcare giant sold stakes in business units to private equity firms Warburg Pincus and KKR &amp; Co. Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KKR#NYSE">KKR</a>) late last year, quietly generating $3.3 billion in profit that helped bolster fourth-quarter earnings.
These transactions, many finalized just before the year-end and kept private even after closing, raised concerns among observers who viewed them as a strategic move to meet earnings targets.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/health-care/25/07/46326465/unitedhealth-slammed-with-another-lawsuit-over-119-billion-stock-plunge" rel="noreferrer noopener">UnitedHealth Slammed With Another Lawsuit Over $119 Billion Stock Plunge</a>
Some deals included terms requiring UnitedHealth to repurchase the stakes later at a higher price, suggesting a temporary earnings boost rather than a long-term gain.
The report on Tuesday <a target="_blank" href="https://www.bloomberg.com/news/features/2025-07-15/how-unitedhealth-quietly-boosted-earnings-with-asset-sales" rel="noreferrer noopener">added</a> that UnitedHealth reported the profits from these sales as part of its operating income and adjusted earnings per share—two key financial metrics—while excluding a $7.1 billion loss from its Brazil business.
The company stated that the Brazil exit was a rare event tied to foreign currency fluctuations, justifying its exclusion under U.S. accounting rules. Critics, however, argue that the selective inclusion and exclusion of such items skews the true picture of the company's performance.
Despite these concerns, UnitedHealth defended its accounting choices, calling them part of routine "portfolio refinement."
UnitedHealth's performance stumbled in early 2025 amid rising Medicare Advantage costs.
The company, which reported underwhelming <a href="https://www.benzinga.com/general/health-care/25/04/44860240/unitedhealth-slashes-2025-outlook-on-medicare-funding-reductions-stock-crashes" target="_blank" rel="noreferrer noopener">first-quarter 2025</a> earnings, suspended its 2025 outlook in May, citing that care activity <a href="https://www.benzinga.com/25/05/45373368/unitedhealth-stock-plunges-names-new-ceo-suspends-2025-guidance" target="_blank" rel="noreferrer noopener">continued to accelerate</a>.
The timing of UnitedHealth&#8217;s earnings is important, especially in light of Centene Corp's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) withdrawal of its 2025 GAAP and adjusted diluted EPS guidance, which stems from its initial review of 2025 industry data from Wakely, an <a href="https://www.benzinga.com/trading-ideas/movers/25/07/46222916/centenes-guidance-withdrawal-spooks-sector-oscar-health-stock-falls" target="_blank" rel="noreferrer noopener">independent actuarial firm</a>.
The company will release its second quarter 2025 financial <a target="_blank" href="https://www.benzinga.com/news/health-care/25/07/46396470/elevance-steps-in-as-unitedhealth-delays-will-it-set-the-tone-for-insurers" rel="noreferrer noopener">results on July 29</a>. Analysts estimate adjusted earnings of $4.95 per share on sales of $111.69 billion, <a target="_blank" href="https://www.benzinga.com/pro/feature/newsfeed" rel="noreferrer noopener">as per data from Benzinga Pro</a>.
Price Action: UNH stock is up 0.34% at $292.70 at the last check on Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/initiation/25/07/46440085/gitlab-bets-big-on-ai-code-explosion-and-wall-streets-buying-in" target="_blank" rel="noreferrer noopener">GitLab Bets Big On AI Code Explosion — And Wall Street&#8217;s Buying In</a></li>
</ul>
Photo: Shutterstock

UnitedHealth's $3.3 Billion Asset Sales Helped Sustain 15-Year Earnings Streak Amid Pressure

Truist Securities analyst Ryan MacDonald maintains Centene (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) with a Buy and lowers the price target from $84 to $42.

Truist Securities Maintains Buy on Centene, Lowers Price Target to $42

Investors with a lot of money to spend have taken a bullish stance on Centene (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>).
And retail traders should know.
We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with CNC, it often means somebody knows something is about to happen.
Today, Benzinga's options scanner spotted 9 options trades for Centene.
This isn't normal.
The overall sentiment of these big-money traders is split between 66% bullish and 33%, bearish.
Out of all of the options we uncovered, there was 1 put, for a total amount of $30,000, and 8, calls, for a total amount of $1,296,575.
<h3>Projected Price Targets</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $20.0 to $47.5 for Centene during the past quarter. 
<h3>Insights into Volume &amp; Open Interest</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Centene's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Centene's whale activity within a strike price range from $20.0 to $47.5 in the last 30 days. 
<h3>Centene Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1752674614_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>CNC</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$10.8</td>
<td>$10.7</td>
<td>$10.7</td>
<td>$25.00</td>
<td>$428.0K</td>
<td>64.9K</td>
<td align="right">424</td>
</tr>
<tr>
<td>CNC</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$13.3</td>
<td>$13.1</td>
<td>$13.2</td>
<td>$20.00</td>
<td>$382.7K</td>
<td>234</td>
<td align="right">0</td>
</tr>
<tr>
<td>CNC</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$13.4</td>
<td>$12.3</td>
<td>$13.3</td>
<td>$20.00</td>
<td>$224.7K</td>
<td>234</td>
<td align="right">290</td>
</tr>
<tr>
<td>CNC</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$10.8</td>
<td>$10.5</td>
<td>$10.8</td>
<td>$25.00</td>
<td>$81.0K</td>
<td>64.9K</td>
<td align="right">507</td>
</tr>
<tr>
<td>CNC</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$10.9</td>
<td>$10.8</td>
<td>$10.8</td>
<td>$25.00</td>
<td>$54.0K</td>
<td>64.9K</td>
<td align="right">474</td>
</tr>
</tbody>
</table>

<h3>About Centene</h3>
Centene is a managed care organization that focuses on government-sponsored healthcare plans, including Medicaid, Medicare, and the individual exchanges. Centene served 22 million medical members as of December 2024, mostly in Medicaid (about 60% of membership), the individual exchanges (about 20%), and Medicare (about 5%). The company also has a military contract and provides Medicare Part D pharmaceutical plans.
After a thorough review of the options trading surrounding Centene, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Centene's Current Market Status</h3>
<ul>
<li>With a volume of 1,684,142, the price of CNC is down -0.47% at $29.86. </li>
<li>RSI indicators hint that the underlying stock may be oversold.</li>
<li>Next earnings are expected to be released in 9 days.</li>
</ul>
<h3>Expert Opinions on Centene</h3>
Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $49.2.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Reflecting concerns, an analyst from UBS lowers its rating to Neutral with a new price target of $45. 
&#x2A; An analyst from Oppenheimer persists with their Outperform rating on Centene, maintaining a target price of $51. 
&#x2A; An analyst from Morgan Stanley has revised its rating downward to Equal-Weight, adjusting the price target to $33. 
&#x2A; Consistent in their evaluation, an analyst from B of A Securities keeps a Neutral rating on Centene with a target price of $52. 
&#x2A; Consistent in their evaluation, an analyst from Cantor Fitzgerald keeps a Overweight rating on Centene with a target price of $65. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Centene with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.

Options

This Is What Whales Are Betting On Centene

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>Barclays analyst Amos Fletcher downgraded the rating for ArcelorMittal S.A. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MT#NYSE">MT</a>) from Overweight to Equal-Weight. ArcelorMittal shares closed at $33.14 on Tuesday. <a href="https://www.benzinga.com/quote/MT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Citigroup analyst Vikram Bagri downgraded Phillips 66 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSX#NYSE">PSX</a>) from Buy to Neutral but raised the price target from $126 to $130. Phillips 66 shares closed at $128.27 on Tuesday. <a href="https://www.benzinga.com/quote/PSX/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>B of A Securities analyst Kevin Fischbeck downgraded the rating for Centene Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) from Neutral to Underperform and lowered the price target from $52 to $30. Centene shares closed at $30.00 on Tuesday. <a href="https://www.benzinga.com/quote/CNC/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Stephens &amp; Co. analyst Tommy Moll downgraded WESCO International, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WCC#NYSE">WCC</a>) from Overweight to Equal-Weight and raised the price target from $190 to $200. WESCO Intl shares closed at $198.14 on Tuesday. <a href="https://www.benzinga.com/quote/WCC/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Goldman Sachs analyst Daniela Costa downgraded CNH Industrial N.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNH#NYSE">CNH</a>) from Buy to Neutral and cut the price target from $12.5 to $11.5. CNH Industrial shares closed at $13.12 on Tuesday. <a href="https://www.benzinga.com/quote/CNH/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/07/46438525/top-3-tech-stocks-that-are-preparing-to-pump-in-july">Top 3 Tech Stocks That Are Preparing To Pump In July</a></li>
</ul>
Photo via Shutterstock

This Centene Analyst Turns Bearish; Here Are Top 5 Downgrades For Wednesday

B of A Securities analyst Kevin Fischbeck downgrades Centene (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) from Neutral to Underperform and lowers the price target from $52 to $30.

B of A Securities Downgrades Centene to Underperform, Lowers Price Target to $30

Oppenheimer analyst Michael Wiederhorn maintains Centene (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) with a Outperform and lowers the price target from $85 to $51.

Oppenheimer Maintains Outperform on Centene, Lowers Price Target to $51

Centene Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) has dropped over 40% in recent sessions, and the decline may be more than just a market reaction. A closer look through the lens of the Adhishthana Principles reveals structural issues that could lead to prolonged underperformance.
<h3 class="wp-block-heading">Monthly Chart: A Breakdown That Changed Everything</h3>
Under the Adhishthana framework, stocks typically build a formation called the Adhishthana Cakra between Phases 4 and 8, a structure resembling a channel with an arc. Ideally, the stock breaks out of this channel in Phase 9, initiating a strong rally.
<figure class="wp-block-image size-full is-resized"><img loading="lazy" decoding="async" width="1200" height="484" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/14053208/CNC-Monthly-Cakra-Breakdown.png" alt="Fig.1 Centene Cakra Breakdown (Source: Adhishthana.com Reports)" class="wp-image-15731" style="width:660px;height:auto" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/14053208/CNC-Monthly-Cakra-Breakdown.png 1200w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/14053208/CNC-Monthly-Cakra-Breakdown-300x121.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/14053208/CNC-Monthly-Cakra-Breakdown-1024x413.png 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/14053208/CNC-Monthly-Cakra-Breakdown-768x310.png 768w" sizes="(max-width: 1200px) 100vw, 1200px" /><figcaption class="wp-element-caption">Fig.1 Centene Cakra Breakdown (Source: Adhishthana.com Reports)</figcaption></figure>
However, Centene broke the Cakra on the flip side, a bearish development that triggers what&#8217;s called the Move of Pralayā in Adhishthana terminology.
<blockquote class="wp-block-quote is-layout-flow wp-block-quote-is-layout-flow">&#8220;When the underlying breaks the Cākra on the flip side, it typically draws consolidation up to the Guna triads. The movement after the break is typically highly significant, and the selling momentum is extremely strong. Such a move shall be called the Move of Pralayā.&#8221; — Adhishthana: The Principles That Govern Wealth, Time &amp; Tragedy
</blockquote>
Centene is now in Phase 7 on the monthly chart, and based on the cycle, it won't complete Phase 13 (the pre-Guna triad phase) until November 30, 2032. That's a long runway of potential weakness, with little structural support to turn the trend around.
<h3 class="wp-block-heading">Weekly Chart: Echoes The Same Story </h3>
The weekly structure echoes the same concerns. Centene is currently in Phase 14, the beginning of the critical Guna Triads (Phases 14–16). These phases collectively determine whether the stock reaches Nirvana (its cycle's peak) in Phase 18.
Unfortunately, this recent decline reflects the energy of Tamoguna, the most bearish of the three energies defined in the Adhishthana Principles.
<blockquote class="wp-block-quote is-layout-flow wp-block-quote-is-layout-flow">&#8220;If the Gūna Triads start from a very strong Tamoguna, there will be no Nirvana in Phase 18.&#8221; — Adhishthana: The Principles That Govern Wealth, Time &amp; Tragedy
</blockquote>
This means Cenetene is unlikely to make any meaningful highs until after October 2028, when the current weekly cycle concludes.
<h3 class="wp-block-heading">Investor Outlook: Not a Normal Correction</h3>
While some might see this as a routine correction, the Move of Pralayā signals something far more serious. This pattern is typically triggered only when there's a fundamental issue with the underlying stock, and in Centene's case, that concern appears justified. 
The company is currently facing allegations of violating federal securities laws, with the investigation covering the period from December 12, 2024, to June 30, 2025. Notably, this timeframe aligns with when Centene began breaking below its Cakra structure, adding weight to the Adhishthana interpretation and reinforcing the principles.
Even minor rallies in this environment are unlikely to be sustainable. And with the monthly chart also in Phase 7, which typically brings a two-fold bearish sequence (known as the Fall of Arthah and Arthārthi), the downside pressure may persist.
What to do now:
<ul class="wp-block-list">
<li>If you&#8217;re already holding CNC, consider your risk exposure carefully. </li>
<li>New investors should avoid chasing dips, as any upside could be short-lived. </li>
<li>Given the long horizon before potential recovery, CNC may not be a stock worth sticking with right now. </li>
</ul>
<h3 class="wp-block-heading">Also Read: </h3>
<a href="https://www.benzinga.com/markets/equities/25/07/46372872/mongodb-stock-weak-structure-suggests-prolonged-slump">MongoDB Stock Weak Structure Suggests Prolonged Slump </a>Recently, MongoDB also broke its Cakra and triggered a Move of Pralayā. Here&#8217;s what that means for long-term investors.

Equities

Technicals

Opinion

Signals

Why Centene's 40% Drop Doesn't Necessarily Signal A Buy

Health insurer Elevance Health Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELV#NYSE">ELV</a>) is scheduled to release its second quarter 2025 financial <a href="https://www.benzinga.com/pressreleases/25/07/b46233308/elevance-health-to-hold-conference-call-and-webcast-to-discuss-second-quarter-2025-results-on-july" target="_blank" rel="noreferrer noopener">results on July 17</a>.
Analysts estimate adjusted earnings of $9.197 per share on sales of $48.24 billion, <a target="_blank" href="https://www.benzinga.com/pro/feature/newsfeed" rel="noreferrer noopener">as per data from Benzinga Pro</a>.
UnitedHealth Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) has been the first major health insurer to report quarterly earnings for several quarters. However, this quarter, the insurance giant will release its second quarter 2025 financial <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/b45734284/unitedhealth-group-announces-earnings-release-date" rel="noreferrer noopener">results on July 29</a>.
As it&#8217;s the biggest player in the industry, Forbes writes that analysts and investors often use its results to gauge the sector&#8217;s overall health.
Also Read: <a href="https://www.benzinga.com/trading-ideas/movers/25/07/46280387/unitedhealth-centene-hit-hard-by-guidance-shock-trumps-medicaid-push" target="_blank" rel="noreferrer noopener">UnitedHealth, Centene Hit Hard By Guidance Shock, Trump&#8217;s Medicaid Push</a>
All eyes will be on the sector after Centene Corp&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) withdrawal of its 2025 GAAP and adjusted diluted EPS guidance, which stems from its initial review of 2025 industry data from Wakely, an <a target="_blank" href="https://www.benzinga.com/trading-ideas/movers/25/07/46222916/centenes-guidance-withdrawal-spooks-sector-oscar-health-stock-falls" rel="noreferrer noopener">independent actuarial firm</a>.
While withdrawing its comprehensive EPS guidance, Centene has reaffirmed its&nbsp;fiscal year 2025 adjusted EPS&nbsp;to be greater than $7.25, aligning with the consensus of $7.23.
UnitedHealth suspended its 2025 outlook in May, citing that care activity <a target="_blank" href="https://www.benzinga.com/25/05/45373368/unitedhealth-stock-plunges-names-new-ceo-suspends-2025-guidance" rel="noreferrer noopener">continued to accelerate</a>.
Earlier in July, managed healthcare service provider under the Medicaid and Medicare programs, Molina Healthcare, Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>), issued preliminary second-quarter results and lowered its full-year 2025 earnings outlook, citing rising medical costs across its Medicaid, Medicare,&nbsp;<a target="_blank" href="https://www.benzinga.com/markets/guidance/25/07/46273556/molina-healthcare-says-higher-medical-cost-trends-bite-cuts-profit-guidance" rel="noreferrer noopener">and state marketplace businesses</a>.
The company expects Q2 adjusted earnings of approximately $5.50 per share—slightly below earlier forecasts—due to expected cost pressures that will persist into the second half of the year.
As a result, Molina cut its full-year 2025 adjusted EPS guidance to $21.50 -$22.50, down from at&nbsp;least $24.50&nbsp;previously. The new forecast reflects a consolidated pre-tax margin just under 4%, at the low end of the company&#8217;s long-term target.
Forbes <a target="_blank" href="https://www.forbes.com/sites/brucejapsen/2025/07/14/eyes-on-elevance-health-not-unitedhealth-as-first-to-report-earnings/" rel="noreferrer noopener">adds</a> Centene&#8217;s announcement is just the latest in a series of updates from health insurers who, over the past two years, have had a hard time managing the costs of people enrolled in government-subsidized health plans.
Price Action: UNH stock is down 1.29% at $300.19 at the last check on Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/07/46394267/why-is-workhorse-stock-tumbling-on-monday" target="_blank" rel="noreferrer noopener">Workhorse Stock Tanks On Merger Talks With Private EV Maker</a></li>
</ul>
Image: Shutterstock

Elevance Steps In As UnitedHealth Delays — Will It Set The Tone For Insurers?

Benzinga examined the prospects for<a href="http://www.benzinga.com/trading-ideas" target="_blank" rel="noreferrer noopener"> many investors' favorite stocks</a> over the last week — here's a look at some of our top stories.
U.S. markets closed this week at record highs, driven by Nvidia (NASDAQ: NVDA) surpassing a $4 trillion market cap — the first ever, marking a historic milestone — amid easing global tensions and broad AI enthusiasm. President Donald Trump's trade rhetoric intensified, with new 50% tariffs planned on copper and Brazilian goods, but markets remained resilient, betting on eventual policy moderation.
Key sectors like airlines and materials also saw gains, while Tesla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) remained under pressure due to Elon Musk's political activities. Gold and the dollar steadied alongside Treasury yields.
Benzinga provides daily reports on the stocks most popular with investors. Here are a few of this past week's most bullish and bearish posts that are worth another look.

The Bulls
<a href="https://www.benzinga.com/trading-ideas/movers/25/07/46321541/nvidia-hits-4-trillion-market-cap-stock-surges-to-all-time-high">"Nvidia hits $4 trillion market cap, stock surges to all‑time high"</a>, by Henry Khederian, reports that Nvidia Corp. (NASDAQ: NVDA) reached a record market valuation above $4 trillion — becoming the first U.S. company to do so — on strong investor momentum, driven by its dominant position in AI chipmaking.
<a href="https://www.benzinga.com/trading-ideas/movers/25/07/46356963/drone-stocks-fly-as-defense-secretary-fast-tracks-drone-production-deployment">"Drone stocks fly as Defense Secretary fast-tracks drone production, deployment"</a>, by Adam Eckert, reports that AeroVironment Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVAV#NASDAQ">AVAV</a>), Kratos Defense &amp; Security Solutions Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KTOS#NASDAQ">KTOS</a>), Red Cat Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCAT#NASDAQ">RCAT</a>), Unusual Machines Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UMAC#NASDAQ">UMAC</a>), AgEagle Aerial Systems Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UAVS#NASDAQ">UAVS</a>), and Ondas Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONDS#NASDAQ">ONDS</a>) all rallied after Defense Secretary Pete Hegseth revoked procurement restrictions and empowered frontline units to fast‑track U.S.-made drone production and deployment.
<a href="https://www.benzinga.com/trading-ideas/long-ideas/25/07/46324594/used%E2%80%91car-boom-prices-supercharging-carvana-autonation-stocks">"Used‑car boom prices supercharging Carvana, AutoNation stocks"</a>, by Adam Eckert, reports that soaring used‑car prices are lifting Carvana Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVNA#NYSE">CVNA</a>) and AutoNation Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AN#NYSE">AN</a>), as both retailers benefit from record-high margins and strong consumer demand in the resale vehicle market.
For additional bullish calls of the past week, check out the following:
<a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/07/46328802/dell-hpe-named-top-ai-server-plays-as-analyst-cites-14b-backlog">Dell, HPE Named Top AI Server Plays As Analyst Cites $14 Billion Backlog</a>
<a href="https://www.benzinga.com/trading-ideas/movers/25/07/46299701/ge-aerospace-climbs-46-in-2025-as-investors-eye-tariff-strategy-earnings">GE Aerospace Climbs 46% In 2025 As Investors Eye Tariff Strategy, Earnings</a>
<a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/07/46353542/palantir-next-oracle-trump-backed-ai-surge">Palantir Is The ‘Next Oracle' On Trump-Backed AI Surge: Analyst</a>

The Bears
<a href="https://www.benzinga.com/analyst-stock-ratings/downgrades/25/07/46308347/trumps-big-beautiful-bill-too-much-for-tesla-stock-direct-hit-to-profitability">"Trump's ‘Big Beautiful Bill' too much for Tesla stock? Direct hit to profitability"</a>, by Shanthi Rexaline, reports that Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) was downgraded by William Blair analyst Jed Dorsheimer, who warned Trump's new bill eliminates $7,500 EV tax credits and corporate average fuel economy fines — putting Tesla's $2.8 billion in annual regulatory credit revenue, 16% of gross profit, at risk.
<a href="https://www.benzinga.com/trading-ideas/movers/25/07/46280387/unitedhealth-centene-hit-hard-by-guidance-shock-trumps-medicaid-push">"UnitedHealth, Centene hit hard by guidance shock, Trump's Medicaid push"</a>, by Vandana Singh, reports that UnitedHealth Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) saw its market cap plunge nearly 41% in Q2 and Centene Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) shares crashed over 40% after Centene withdrew its 2025 guidance — moves driven by unexpectedly high medical costs and President Donald Trump's new legislation targeting Medicaid funding that threatens insurers' risk pools and reimbursement structures.
<a href="https://www.benzinga.com/trading-ideas/movers/25/07/46348352/gorilla-technology-shares-plunge-after-nvidia-fueled-rally-reverses">"Gorilla Technology shares plunge after Nvidia‑fueled rally reverses"</a>, by Akanksha Bakshi, reports that Gorilla Technology Group Inc. (NASDAQ: GRRR) stock tumbled after a brief surge drove by its inclusion as an NVIDIA Solutions Partner on Nvidia's website—without any formal announcement—reversing the prior day's strong rally.
For more bearish takes, be sure to see these posts:
<a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/07/46352461/core-scientific-downgraded-over-concerns-on-acquisition-deal">Core Scientific Downgraded Over Concerns On Acquisition Deal</a>
<a href="https://www.benzinga.com/markets/tech/25/07/46374969/jpmorgan-just-hit-delete-on-tesla-and-rivian">JPMorgan Just Hit ‘Delete' On Tesla And Rivian</a>
<a href="https://www.benzinga.com/news/health-care/25/07/46326465/unitedhealth-slammed-with-another-lawsuit-over-119-billion-stock-plunge">UnitedHealth Slammed With Another Lawsuit Over $119 Billion Stock Plunge</a>

Keep up with all the latest breaking news and trading ideas by following <a href="https://twitter.com/Benzinga" target="_blank" rel="noreferrer noopener">Benzinga</a><a href="http://twitter.com/Benzinga" target="_blank" rel="noreferrer noopener"> on X</a>.
Image created using artificial intelligence via Midjourney.

AVAV

Core Scientific, Inc. - Class A Common Stock

CORZ

CVNA

DELL

GRRR

KTOS

NVDA

ONDS

PLTR

RCAT

RIVN

TSLA

UAVS

UMAC

Benzinga Bulls And Bears: Nvidia, Tesla, Carvana — And Trump Amps Up Tariff Talk

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>Citigroup raised Avery Dennison Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AVY#NYSE">AVY</a>) price target from $177 to $185. Citigroup analyst Anthony Pettinari maintained a Neutral rating. Avery Dennison shares closed at $182.21 on Friday. <a href="https://www.benzinga.com/quote/avy/analyst-ratings">See how other analysts view this stock.</a></li>
<li>JP Morgan boosted the price target for Synchrony Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYF#NYSE">SYF</a>) from $52 to $80. JP Morgan analyst Richard Shane maintained an Overweight rating. Synchrony Financial shares closed at $70.61 on Friday. <a href="https://www.benzinga.com/quote/syf/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Piper Sandler raised Netflix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) price target from $1,150 to $1,400. Piper Sandler analyst Matt Farrell maintained an Overweight rating. Netflix shares closed at $1,245.11 on Friday. <a href="https://www.benzinga.com/quote/nflx/analyst-ratings">See how other analysts view this stoc</a>k.</li>
<li>JP Morgan boosted the price target for Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) from $195 to $200. JP Morgan analyst Doug Anmuth maintained an Overweight rating. Alphabet shares closed at $181.31 on Friday. <a href="https://www.benzinga.com/quote/goog/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Mizuho cut the price target for Centene Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) from $71 to $40. Mizuho analyst Ann Hynes maintained a Neutral rating. Centene shares closed at $31.44 on Friday. <a href="https://www.benzinga.com/quote/cnc/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Morgan Stanley raised DraftKings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DKNG#NASDAQ">DKNG</a>) price target from $51 to $52. Morgan Stanley analyst Stephen Grambling maintained an Overweight rating. DraftKings shares settled at $42.98 on Friday. <a href="https://www.benzinga.com/quote/dkng/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Evercore ISI Group increased Hewlett Packard Enterprise Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HPE#NYSE">HPE</a>) price target from $22 to $25. Evercore ISI Group analyst Amit Daryanani maintained an Outperform rating. Hewlett Packard Enterprise shares closed at $20.72 on Friday. <a href="https://www.benzinga.com/quote/hpe/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Goldman Sachs cut Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) price target from $315 to $285. Goldman Sachs analyst Mark Delaney maintained a Neutral rating. Tesla shares closed at $313.51 on Friday.  <a href="https://www.benzinga.com/quote/tsla/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Stifel raised the price target for Starbucks Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NASDAQ">SBUX</a>) from $92 to $105. Stifel analyst Chris O&#8217;Cull maintained a Buy rating. Starbucks shares settled at $94.94 on Friday. <a href="https://www.benzinga.com/quote/sbux/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Truist Securities cut Lockheed Martin Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMT#NYSE">LMT</a>) price target from $579 to $554. Truist Securities analyst Michael Ciarmoli maintained a Buy rating. Lockheed Martin shares closed at $467.51 on Friday. <a href="https://www.benzinga.com/quote/lmt/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying TSLA stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="577" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/12033335/image-141-1024x577.png" alt="" class="wp-image-982691" style="width:630px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/12033335/image-141-1024x577.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/12033335/image-141-300x169.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/12033335/image-141-768x433.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/12033335/image-141.png 1118w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/dividends/25/07/46364470/how-to-earn-500-a-month-from-citigroup-stock-ahead-of-q2-earnings">How To Earn $500 A Month From Citigroup Stock Ahead Of Q2 Earnings</a> </li>
</ul>
Photo via Shutterstock

DKNG

GOOG

NFLX

SBUX

Tesla To $285? Here Are 10 Top Analyst Forecasts For Friday

Legal

Press Releases

CNC SECURITIES NEWS: Did Centene Corporation (NYSE:CNC) Commit Securities Fraud? Contact BFA Law by September 8 Class Action Deadline

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Centene

Centene Corporation Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - CNC

The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Centene Corporation(CNC) Shareholders

INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Centene Corporation (CNC) Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit

Important Notice to Long-Term Shareholders of Capricor Therapeutics, Inc. (NASDAQ: CAPR); Centene Corporation (NYSE: CNC); DoubleVerify Holdings, Inc. (NYSE: DV); and Treace Medical Concepts, Inc. (NASDAQ: TMCI); Grabar Law Office is Investigating Claims on Your Behalf

CNC Investors Have Opportunity to Join Centene Corporation Fraud Investigation with the Schall Law Firm

Centene Corporation (CNC) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Centene Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action – CNC

Comments

Centene

Centene (CNC) Options

Centene (NYSE:CNC) Stock, Chaîne d'Options

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL